Atypical Teratoid/Rhabdoid Tumor (ATRT)

Atypical Teratoid/Rhabdoid Tumor (ATRT): A Rare but Aggressive Pediatric Brain Cancer

Atypical Teratoid/Rhabdoid Tumor (ATRT) is an aggressive and rare form of brain cancer that mostly occurs in young children, usually under three years of age. Its high growth rate and resistance to treatment make ATRT a challenge in pediatric oncology. Though it occurs infrequently, at only 1-2% of all childhood brain tumors, its high mortality rate and multifaceted biology have made it a focus of research and therapeutic development.

Understanding ATRT

ATRT is a central nervous system (CNS) tumor and is most frequently encountered in the cerebellum, where it regulates movement and coordination. It can occur anywhere in the brain or spinal cord. The tumor is highly malignant with rapid progression and a propensity to spread through the CNS.

The underlying genetic mutation causing ATRT is the SMARCB1 gene (equivalently known as INI1, hSNF5, or BAF47), which is a tumor suppressor gene. SMARCB1 plays an essential function in the process of chromatin remodeling as well as in cell differentiation. The loss of function or absence of SMARCB1 can cause uncontrollable growth of the cells and tumors. Mutations in the SMARCA4 gene may sometimes play a rare causative role.

Causes and risk factors

The precise etiology of ATRT is still unknown, but it is not usually related to environmental or hereditary factors. Nevertheless, in a few instances, ATRT may be related to genetic syndromes, including Rhabdoid Tumor Predisposition Syndrome (RTPS), which is inherited in an autosomal dominant manner. RTPS predisposes one to the development of multiple rhabdoid tumors in various regions of the body.

Symptoms of ATRT

The symptoms of ATRT vary depending on the tumor’s location, size, and the age of the child. Common symptoms include:

• Increased Intracranial Pressure (ICP): Headaches, vomiting (especially in the morning), and lethargy due to tumor growth blocking cerebrospinal fluid (CSF) flow.
• Neurological Symptoms: Weakness, seizures, difficulties in coordination and balance, and vision problems.
• Developmental Delays: Regression in motor skills, speech, and social interactions in young children.
• Behavioral Changes: Irritability, excessive sleepiness, or personality shifts.
• Hydrocephalus: Swelling of the brain due to CSF accumulation, leading to increased head size in infants.

Diagnosis of ATRT

Diagnosing ATRT requires a combination of imaging, biopsy, and genetic testing. The key diagnostic tools include:

• Magnetic Resonance Imaging (MRI): Provides detailed images of the brain and spinal cord to locate the tumor.
• Computed Tomography (CT) Scan: Helps identify calcifications or hemorrhages associated with the tumor.
• Biopsy and Histopathology: Examination of tumor tissue under a microscope to confirm rhabdoid cell characteristics.
• Genetic Testing: Analysis of SMARCB1/INI1 gene mutations to differentiate ATRT from other CNS tumors.
• Lumbar Puncture (Spinal Tap): Checks for cancerous cells in the cerebrospinal fluid to assess tumor spread.

Treatment Options for ATRT

ATRT is challenging to treat due to its aggressive nature and the young age of affected children, limiting certain therapeutic options. The standard treatment approach includes a combination of surgery, chemotherapy, and radiation therapy.

1. Surgery

Surgical resection is the first step in treatment, aiming to remove as much of the tumor as possible. However, complete removal is often difficult due to the tumor’s location and infiltration into critical brain structures. In many cases, residual tumor cells remain, necessitating further treatment.

2. Chemotherapy

Chemotherapy plays a crucial role in ATRT treatment, often used in conjunction with surgery and radiation. High-dose chemotherapy with stem cell rescue (autologous stem cell transplantation) is sometimes employed to improve survival rates. Common chemotherapeutic agents include:

• Vincristine
• Cisplatin
• Cyclophosphamide
• Etoposide
• Methotrexate

3. Radiation Therapy

Radiation therapy is highly effective in controlling ATRT but is limited in young children due to potential long-term cognitive and developmental side effects. However, focal radiation or proton beam therapy, which minimizes damage to surrounding tissues, is increasingly used in older children.

4. Targeted Therapy and Immunotherapy

Given the poor prognosis of ATRT, researchers are investigating novel targeted therapies and immunotherapy options, including:

• Bromodomain inhibitors (BET inhibitors): Target epigenetic mechanisms in ATRT.
• EZH2 inhibitors: Target the epigenetic regulator EZH2, which is overactive in ATRT.
• Immune Checkpoint Inhibitors: Enhance the body’s immune response to the tumor.
• CAR T-cell Therapy: Genetically engineered immune cells to attack ATRT cells.

Prognosis and Survival Rates

The prognosis for ATRT remains poor, with a median survival of less than two years in most cases. The 5-year survival rate is approximately 10-30%, though some children treated with multimodal therapy achieve longer survival. Prognostic factors include:

• Age at Diagnosis: Younger patients (<3 years) have worse outcomes.
• Extent of Surgical Resection: Complete removal improves survival chances.
• Metastasis at Diagnosis: Tumors that have spread have a lower survival rate.
• Response to Therapy: Some children respond better to aggressive treatment approaches.

Recent Advances in ATRT Research

Scientific advancements are gradually improving ATRT outcomes. Research focuses on:

• Genomic Studies: Understanding ATRT subtypes to develop personalized therapies.
• Clinical Trials: Evaluating new drugs, immunotherapies, and combination treatments.
• Liquid Biopsy Techniques: Early detection through blood or CSF biomarkers.
• Gene Therapy Approaches: Restoring SMARCB1 function in tumor cells.

Living with ATRT: Support for Families

Caring for a child with ATRT is emotionally and physically demanding. Support resources include:

• Pediatric Neuro-Oncology Teams: Specialized care for managing treatment side effects.
• Clinical Trials and Experimental Treatments: Access to cutting-edge therapies.
• Psychosocial Support: Counseling for the emotional well-being of families.
• Palliative Care: Symptom management and quality-of-life improvement in advanced cases.

Conclusion

Atypical Teratoid/Rhabdoid Tumor is one of the most difficult to treat pediatric cancers because it is highly aggressive and has few treatment options. Despite low survival rates, research on targeted therapy, immunotherapy, and genetic medicine gives promise for improved results in the future.

Heightening awareness, aiding victimized families, and furthering scientific study are essential steps toward combating ATRT. If your child is diagnosed with ATRT, treatment in specialized pediatric cancer hospitals and clinical trials can enhance survival rates and quality of life.

• Comments Closed
• March 5th, 2025